Back to results
US 2003/0148958 A1Published application
Corticotropin releasing factor 2 receptor agonists
AssigneeThe Procter & Gamble Company
InventorsRobert Joseph Isfort, Wieslaw Adam Mazur
Life of this patent
Estimating the term…
Abstract
Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
Claims52
A non-native peptide according to the formula:
- alpha-beta-gamma-delta-epsilon-zeta-eta-theta
- wherein:
- a. alpha comprises a sequence of a formula X1X2X3 X4X5X6, wherein:
- X1, X2 and X3 are each selected from the group consisting of nil, A, E, D, G, N, P, Q, S, T, and Z;
- X4 is selected from the group consisting of F, I, L, P, T and V;
- X5 is selected from the group consisting of A, I, P, S, T and V;
- X6 is selected from the group consisting of I, L, M and N;
- b. beta comprises a sequence of a formula SX8DX10, wherein:
- X8 and X10 are each independently selected from the group consisting of I, L and V;
- c. gamma comprises a sequence of a formula X1 X12X13, wherein:
- X11, is selected from the group consisting of P, S, V, and T;
- and
- X12 and X13 are each independently selected from the group consisting of A, Naphthylalanine, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;
- d. delta comprises a sequence of a formula X14X15X16, wherein:
- X14 is selected from the group consisting of I, L, and M;
- X15 is selected from L and M;
- and
- X16 is selected from the group consisting of S, N, Q, and R;
- e. epsilon comprises a sequence of a formula X17X18X19X20X21, wherein:
- X17 is selected from the group consisting of V, I, L, T, K, E, N, and Q;
- X18 is selected from the group consisting of L, M, V, A, and T;
- X19 is selected from the group consisting of I, F, L, and M;
- X20 is selected from the group consisting of D, E, N, and H;
- and
- X21 is selected from the group consisting of L, V, I, Q, M, and R;
- f. zeta comprises a sequence of a formula X22X23X24X25, wherein:
- X22 is selected from the group consisting of nil, A, D, E, S, and T;
- X23 is selected from the group consisting of nil, K and R;
- X24 is selected from the group consisting of nil, A H, M, N, Q, T, and Y;
- X25 is selected from the group consisting of nil, E, D, I, K, N, Q, and R;
- g. eta comprises a sequence of the formula X26X27X28X29X30X31, wherein:
- X26 is selected from the group consisting of A, D, G, H, K, N, Q, and S;
- X27 is selected from the group consisting of A, E, I, L, M, and Q;
- X28 is selected from the group consisting of A, K, H, Q, R, and V;
- X29 is selected from the group consisting of A, E, K, M, N, and Q;
- X30 is selected from the group consisting of H, K, N, Q, and R;
- X31 is selected from the group consisting of A and K;
- h. theta comprises a sequence of the formula X32X33NX35X36X37X38X39X40X41, wherein:
- X32 is selected from the group consisting of A, E, H and T;
- X33 is selected from the group consisting of A, D, E, I, L, N, Q, R, S and T;
- X35 is selected from the group consisting of A and R;
- X36 is selected from the group consisting of E, H, I, K, L, N, Q and R;
- X37 is selected from the group consisting of F, I, L, M and Y;
- X38 is selected from the group consisting of L, F and M;
- X39 is selected from the group consisting of A, D, E, N and Q;
- X40 is selected from the group consisting of A, D, E, H, I, K, N, Q, R, S and T;
- X41 is selected from the group consisting of A, F, I and V;
- and variants thereof.
45 more elements
Dependencies are inferred from the claim text.